美国血液学会（ASH)认定：1995年三氧化二砷治疗急性早幼粒细胞白血病获成功

——张鹏等人关于三氧化二砷（ATO）治疗急性早幼粒细胞白血病成功的研究被美国血液学会（ASH）认定为《血液病学50年大事记》

美国血液学会(ASH)是世界各国血液学专家学者组成的国际学术团体。2008年，ASH年会为纪念 ASH光辉的50年专门出版了：回顾近50年中血液学的发展历程，并论述了血液学的最新成果（2008年12月6日至9日，在旧金山）。据《血液病学50年大事记》记载，“（第7项）1995年中国哈尔滨学者应用三氧化二砷治疗急性早幼粒细胞白血病（APL)（含复发）获成功，并创立了肿瘤凋亡治疗学”。（BLOOD DETECTIVES As seen on Discovery Health WWW.blooddetectives.org）。

被 ASH 提及的哈尔滨学者的研究成果，也就是哈医大一院血液内科的张鹏教授与其同事1995年发表的论著：“713,（ATO）”治疗急性早幼粒细胞白血病117例临床观察及机制探讨（摘要）（哈尔滨医科大学学报1995,29(3):243），本文包含了ATO对APL初治及复发组疗效、副作用及机制（诱导白血病细胞分化和诱导其凋亡）。此外，张鹏等学者还在国内外领先发表了两篇论著：第一篇，三氧化二砷注射液治疗急性早幼粒细胞白血病72例（中华血液学杂志 1996,17(2):58-60）；第二篇，三氧化二砷治疗急性早幼粒细胞白血病机制（白血病杂志1996,5(3):131-133）。此后，ATO治疗APL便开始在国内推广，继而在国外应用，其中包含“诱导凋亡”做为治疗肿瘤药物主要筛选方法。

哈医大一院血液内科张鹏等学者的“ATO治疗APL的临床与机制研究”这项成果也获得了如下奖项：1996年获黑龙江省医药卫生科技进步奖、1997年获黑龙江省科技进步奖和1998年获国家卫生部重大科技贡献奖。

《新华社》在1999年3月17日向全世界宣布了这项对国际医学有重大贡献的研究成果。《美国世界日报》和《澳门日报》等诸多报刊也对该项成果进行了报道，报导如下：“《新华社哈尔滨十七日电》中国医生从民间验方中发现砷剂可能是治疗早幼粒细胞白血病的有效方法。目前，中国首先采用的这种砷剂疗法，已成为现代药物治疗白血病这一世界难题的研究主流，成为国际血液病研究的热点之一。……一九九二年，哈尔滨医科大学附属第一医院血液科张鹏教授与同事们从中外医学文献有关砷剂的记载中找到了灵感，采用单一的三氧化二砷注射液，进行治疗早幼粒白血病的临床与机理研究，结果发现疗效显著。张鹏等人的研究成果在国际医学界引起了轰动。专家说：这是中国在药物治疗白血病研究中取得的突破性成果，已达到国际领先水平。目前，这种疗法已被中国多家医院采用，对大量中外患者的治疗都取得了令人鼓舞的效果。”

遗憾的是，由于不同意将这项成果让给当时的院长，张鹏在1999年被迫提前退休，张鹏的退休与离开医院给一些妄图窃取者创造了条件与机遇。2016年至2018年，张亭栋、周晋等人连续三年以“亚砷酸注射液（即ATO）治疗急性早幼粒细胞白血病”申报国家发明奖，但三次申报均被否决。第二年，张亭栋、周晋等人又以“癌灵1号注射液治疗急性早幼粒细胞白血病研究”申报国家科技进步奖，这次又被否决。国家奖励办公室和评审专家们公允的行为保护了张鹏等人的“知识产权”，更重要的是，该行为维护了学术界的公平正义。

作者：来釆风  祯祥jqz

The American Hematological Society (ASH) determined that arsenic trioxide was successful in the treatment of acute promyelocytic leukemia in 1995.

—Zhang Peng et al.'s successful research on arsenic trioxide (ATO) in the treatment of acute promyelocytic leukemia was recognized by the American Hematological Society (ASH) as "50 Years of Events in Hematology"

    The American Blood Society (ASH) is an international academic group of experts and scholars in hematology from all over the world. In 2008, the annual meeting of ASH was dedicated to commemorating the glorious 50 years of ASH: reviewing the development of hematology in the past 50 years and discussing the latest achievements of hematology (San Francisco, December 6-9, 2008). According to the 50 Years of Hematology (7), "In 1995, scholars in Harbin, China successfully applied arsenic trioxide to treat acute promyelocytic leukemia (APL) (including recurrence) and created the treatment of tumor apoptosis". (BLOOD DETECTIVES As Seen on DiscoveryHealth WWW.blooddetectives.org)

    The research results of Harbin scholars mentioned by ASH, that is, Professor Zhang Peng of the Department of Hematology of the First Hospital of Harbin Medical University and his colleagues published a speech in 1995: "713(ATO)" Clinical Observation and Mechanism of 117 Cases of Acute Promyelocytic Leukemia (Abstract) (June of Harbin Medical University) 1995.29(3):243), this article contains the efficacy, side effects and mechanisms of ATO in the initial treatment and recurrence group of APL (inducing leukemia cell differentiation and inducing apoptosis). In addition, Zhang Peng and other scholars have also taken the lead in publishing two papers at home and abroad: the first, arsenic trioxide injection in the treatment of 72 cases of acute promyelocytic leukemia (Chinese Journal of Hematology 1996,17(2)58-60); the second, the mechanism of arsenic trioxide in the treatment of acute promyelocytic leukemia (Chinese  leukemia,1996.5(3):131-133). Since then, ATO treatment APL has been popularized in China and then applied abroad, including "induced apoptosis" as the main screening method for tumor treatment drugs.

    Zhang Peng and other scholars from the Department of Hematology of the First Hospital of Harbin Medical University also won the following awards: Heilongjiang Medical and Health Science and Technology Progress Award in 1996, Heilongjiang Science and Technology Progress Award in 1997, and major scientific and technological contributions from the Ministry of Health in 1998. 

    Xinhua News Agency announced the results of this research that has made a significant contribution to international medicine to the world on March 17, 1999. Many newspapers and magazines, such as the World Daily and the Macao Daily, also reported the results as follows: "Xinhua News Agency, Harbin, 17th, Chinese doctors found an effective method of arsenic in the treatment of promyelocytic leukemia from folk prescriptions. At present, the first arsenic therapy used in China has become the mainstream of modern drug treatment of leukemia, which is a world problem, and has become one of the hot spots in international blood disease research... In 1992, Professor Zhang Peng of the Department of Hematology of the First Affiliated Hospital of Harbin Medical University and his colleagues found inspiration from the records of arsenic agents in Chinese and foreign medical literature. A single arsenic trioxide injection was used to study the clinical and mechanism of the treatment of promyelocytic leukemia. The results showed that the curative effect was significant. The research results of Zhang Peng and others have caused a sensation in the international medical community. Experts say: This is a breakthrough achievement in China's research on drug treatment of leukemia, which has reached the international leading level. At present, this treatment has been adopted by many hospitals in China, and the treatment of a large number of Chinese and foreign patients has achieved encouraging results."

    Unfortunately, Zhang Peng was forced to retire early in 1999 because he did not agree to give up this result to the then president. Zhang Peng's retirement and departure from the hospital created conditions and opportunities for some people who tried to steal it. From 2016 to 2018, Zhang Tingdong, Zhou Jin and others applied for the National Invention Award for the Treatment of Acute Promyelocytic Leukemia with Arsenic Acid Injection (i.e. ATO) for three consecutive years, but all three telegrams were rejected. The next year, Zhang Tingdong, Zhou Jin and others applied for the National Science and Technology Progress Award with "Research on the Treatment of Acute Promyelocytic Leukemia Leukemia with Cancer No. 1 Injection", which was rejected this time. The fair behavior of the National Award Office and evaluation experts protects the "intellectual property rights" of Zhang Peng and others. More importantly, this behavior upholds fairness and justice in academia.

      Lai Caifeng ，Zhen Xiangjqz